


PHARMACEUTICAL 2019



Clovis Oncology Inc. Rank 192 of 371



RealRate

PHARMACEUTICAL 2019



Clovis Oncology Inc. Rank 192 of 371

The relative strengths and weaknesses of Clovis Oncology Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Clovis Oncology Inc. compared to the market average is the variable Expenses, increasing the Economic Capital Ratio by 34% points. The greatest weakness of Clovis Oncology Inc. is the variable Other Liabilities, reducing the Economic Capital Ratio by 24% points.

The company's Economic Capital Ratio, given in the ranking table, is -169%, being 162% points above the market average of -331%.

Input Variable	Value in 1000 USD
Assets, Current	572,299
Cost of Goods Sold	0
Intangible Assets	115,004
Liabilities, Current	125,749
Liabilities, Non-Current	0
Other Assets	149,733
Other Compr. Net Income	-2,461
Other Expenses	22,682
Other Liabilities	591,342
Other Net Income	-33,587
Property and Equipment	26,524
Research and Development	231,347
Revenues	95,388
Selling, General and Administrative Expense	175,781

Output Variable	Value in 1000 USD
Assets	863,560
Liabilities	717,091
Expenses	429,810
Stockholders Equity	146,469
Net Income	-368,009
Comprehensive Net Income	-369,240
Economic Capital Ratio	-169%